FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.
Metrics to compare | 4881 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4881PeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −5.6x | −0.7x | |
PEG Ratio | 0.07 | 0.00 | 0.00 | |
Price/Book | 1.8x | 4.5x | 2.6x | |
Price / LTM Sales | 730.1x | 43.5x | 3.4x | |
Upside (Analyst Target) | - | 92.6% | 37.9% | |
Fair Value Upside | Unlock | 20.7% | 5.2% | Unlock |